☆ 4.7 Article

The Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study

VACCINES (2022)

Related references

Note: Only part of the references are listed.

Review Rheumatology

Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations

Feline P. B. Kroon et al.

Summary: This systematic literature review on patients with rheumatic and musculoskeletal diseases (RMDs) examined the risk and prognosis of SARS-CoV-2 infection as well as the vaccination against SARS-CoV-2. Most studies indicated that individuals with RMDs do not have a higher risk of contracting SARS-CoV-2 or experiencing worse COVID-19 outcomes compared to those without RMDs. Disease activity and medication use may influence the prognosis of COVID-19.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Rheumatology

Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus

Ernesto Zavala-Flores et al.

Summary: This study aimed to identify post-vaccination side effects of the SARS-CoV-2 vaccine BNT162b2 in patients with systemic lupus erythematosus at Cayetano Heredia Hospital in Lima, Peru. The study found that the majority of patients experienced mild symptoms within 10 days after vaccination, with pain at the injection site being the most common. Additionally, there was a significant association between a history of renal involvement, prior use of hydroxychloroquine and azathioprine, and the risk of developing post-vaccination flare in SLE patients.

CLINICAL RHEUMATOLOGY (2022)

Add to Collection

Article Rheumatology

Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination

Peter M. Izmirly et al.

Summary: In a multiethnic/multiracial study of SLE patients, 29% had a low response to the COVID-19 vaccine which was associated with receiving immunosuppressive therapy. Severe disease flares were rare.

ARTHRITIS & RHEUMATOLOGY (2022)

Add to Collection

Letter Rheumatology

How to use the Lupus Low Disease Activity State (LLDAS) in clinical trials

Ioannis Parodis et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Editorial Material Rheumatology

Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study Comment

Renaud Felten et al.

LANCET RHEUMATOLOGY (2021)

Add to Collection

Article Rheumatology

Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004-2015

Edward R. Hammond et al.

Summary: The study found that the frequency and severity of flares in newly diagnosed patients with SLE increase with disease severity. Healthcare costs increase over the following 90 days after a flare, depending on the severity of the disease. Preventing flares or reducing flare rates and duration may improve outcomes and reduce healthcare costs.

LUPUS SCIENCE & MEDICINE (2021)

Add to Collection

Letter Rheumatology

Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases

Caoilfhionn M. Connolly et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

The Use of COVID-19 Vaccines in Patients with SLE

Wei Tang et al.

Summary: This review highlighted the lack of evidence on the safety and efficacy of COVID-19 vaccines in patients with autoimmune inflammatory rheumatic diseases (AIIRD), with a focus on systemic lupus erythematosus (SLE). Although patients with SLE may have weaker immune responses to the vaccines, there is no significant safety concern associated with vaccination in AIIRD patients. Further studies are needed to determine the optimal vaccination strategies and adjust immunosuppressants accordingly.

CURRENT RHEUMATOLOGY REPORTS (2021)

Add to Collection

Review Immunology

Challenges to Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Diseases

Giuseppe A. Ramirez et al.

Summary: Aberrant deployment of the immune response is a key feature of COVID-19, with vaccination against SARS-CoV-2 being effective and safe for patients with immune-mediated diseases. However, tailored strategies are needed for these patients to optimize vaccination outcomes, especially for those with primary immunodeficiencies. Additional data is necessary for this specific patient population to further understand the impact of vaccination.

VACCINES (2021)

Add to Collection

Letter Rheumatology

Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies

Savino Sciascia et al.

LANCET RHEUMATOLOGY (2021)

Add to Collection

Review Immunology

Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Ali Pormohammad et al.

Summary: This study systematically reviewed the clinical features of COVID-19 vaccines in clinical trials, finding that mRNA-based and adenovirus-vectored vaccines exhibited different efficacy and side effect profiles. Both types of vaccines showed high efficacy after the first and second doses, with mRNA-based vaccines having higher reported side effects.

VACCINES (2021)

Add to Collection

Letter Rheumatology

Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City

Medha Barbhaiya et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Review Rheumatology

Lupus, vaccinations and COVID-19: What we know now

Alice Mason et al.

Summary: SARS-CoV-2 has caused significant impact on health services, particularly affecting patients with SLE who may be at higher risk of poor outcomes with COVID-19. Multiple vaccines have been authorized temporarily, but concerns remain about their effectiveness in SLE patients, especially those on specific treatments like rituximab or high dose steroids. Further research and data collection are needed to evaluate the impact of vaccination on SLE disease control and the severity of COVID-19 in SLE patients.

LUPUS (2021)

Add to Collection

Article Rheumatology

Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey

Somy Cherian et al.

Summary: The study found that there were no significant differences in adverse reaction rates between patients with autoimmune rheumatic diseases (AIRD) and non-AIRD after receiving the ChAdOx1 or BBV152 vaccines, confirming the safety of the vaccines in rheumatic and musculoskeletal diseases (RMDs).

RHEUMATOLOGY INTERNATIONAL (2021)

Add to Collection

Article Rheumatology

Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis

Lars Erik Bartels et al.

Summary: The study investigates the safety and reactogenicity of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine among patients with SLE and RA. Most patients experienced either local or systemic reactions within seven days after vaccination, with severe reactions being rare.

RHEUMATOLOGY INTERNATIONAL (2021)

Add to Collection

Review Rheumatology

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

Victoria Furer et al.

ANNALS OF THE RHEUMATIC DISEASES (2020)

Add to Collection

Review Immunology

Systemic lupus erythematosus and risk of infection

Megan R. W. Barber et al.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2020)

Add to Collection

Article Rheumatology

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

Martin Aringer et al.

ANNALS OF THE RHEUMATIC DISEASES (2019)

Add to Collection

Review Medicine, General & Internal

Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon?

Maria Vadala et al.

EPMA JOURNAL (2017)

Add to Collection

Article Rheumatology

Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials

Michelle A. Petri et al.

ARTHRITIS AND RHEUMATISM (2013)

Add to Collection

Article Rheumatology

Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety

Ewa Wiesik-Szewczyk et al.

CLINICAL RHEUMATOLOGY (2010)

Add to Collection

Article Rheumatology

Ten cases of systemic lupus erythematosus related to hepatitis B vaccine

N. Agmon-Levin et al.

LUPUS (2009)

Add to Collection

Article Rheumatology

BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus

DA Isenberg et al.

RHEUMATOLOGY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.